MarketPulse

GLP-1 medicine

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Amgen and Merck Emerge as Defensive Dividend Plays Amid Economic Uncertainty

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.
AMGNMRKbiotechpharmaceuticals
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs